The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | How single-cell technologies are reshaping lymphoma immunotherapy
Sandrine Roulland, PharmD, PhD, Center for Immunology of Marseille-Luminy (CIML), Marseille, France, discusses how single-cell and spatial analyses are advancing understanding of the lymphoma tumour microenvironment. She highlights the identification of cellular ecosystems that may predict response to immunotherapy and explains how integrating these technologies into clinical trials could support future AI-driven pathology tools and more personalised treatment strategies. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in the session on microenvironment in lymphoid malignancies, we have two talks looking at the spatial organization of the tumor. So now, with single-cell analysis, we are starting to explore the heterogeneity of B-cell lymphoma and DLBCL and follicular, most importantly. And in those two diseases, we have been able to define cellular communities and cellular ecosystems that are characterizing the heterogeneity of the tumor cells and also the heterogeneity of the microenvironment...
So in the session on microenvironment in lymphoid malignancies, we have two talks looking at the spatial organization of the tumor. So now, with single-cell analysis, we are starting to explore the heterogeneity of B-cell lymphoma and DLBCL and follicular, most importantly. And in those two diseases, we have been able to define cellular communities and cellular ecosystems that are characterizing the heterogeneity of the tumor cells and also the heterogeneity of the microenvironment. So right now we are more at the descriptive level, so we are defining communities, certain cell states, certain B-cell states that are aggregating with certain cell types of the tumor microenvironment. So we are defining some ecosystems. At that time, we are more at the discovery level and the next step will be to define how those ecosystems make sense in terms of the clinics. Do they predict better response to therapy? Do they predict better response to immunotherapy? So I think we need more samples to be analyzed and also more in the context of clinical trials, because for now, most of the studies have been done in real life, so with a heterogeneous population. And so really to be meaningful and to adapt to those characterizations at the single-cell level, at the spatial level, we need really to insert this type of approach in the context of clinical trials. And I think there is emerging data that were not yet mature to be presented at this ASH meeting, but if we can define some ecosystems at the spatial level and at the single-cell level, and we can map that directly on a slide and through digital pathology, so maybe we will have a tool with digital pathology and an AI model on FFPE slides to be developed in the context of clinical trials. But this transition between the discovery part on the spatial level and the digital pathology part is really something that is ongoing right now and is really the future of this approach.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
